Tyra Biosciences Appoints Biotech Veteran Habib J. Dable to Board of Directors

summarizeSummary

Tyra Biosciences, Inc. has expanded its board and appointed Habib J. Dable, a seasoned biopharmaceutical executive with extensive leadership and board experience, as a new independent director.

check_boxKey Events

• Board Expansion and New Appointment

  The Board of Directors approved an increase in authorized directors from nine to ten and appointed Habib J. Dable as a Class II independent director, effective April 16, 2026.

• Highly Experienced Biopharma Executive Joins Board

  Mr. Dable brings a strong background, including serving as President and CEO of Acceleron Pharma Inc. (acquired by Merck), holding senior roles at Bayer AG, and currently advising RA Capital Management, L.P. He also serves on the boards of several other life sciences companies.

• Standard Director Compensation

  In connection with his appointment, Mr. Dable was granted options to purchase 44,400 shares of common stock, vesting over 36 months, and will receive cash compensation in accordance with the company's Non-Employee Director Compensation Program.

auto_awesomeAnalysis

The appointment of Habib J. Dable significantly strengthens Tyra Biosciences' board with a highly experienced biopharmaceutical executive. His background as a former CEO of Acceleron Pharma (acquired by Merck), extensive leadership roles at Bayer AG, and current advisory position at RA Capital Management, L.P., brings valuable strategic and operational expertise, particularly in drug development and corporate growth. This move enhances governance and could provide critical guidance as the company progresses its clinical pipeline, as highlighted in its recent 10-K.